Gary Calandra

2.2k total citations · 1 hit paper
41 papers, 1.7k citations indexed

About

Gary Calandra is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, Gary Calandra has authored 41 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Hematology, 13 papers in Oncology and 8 papers in Immunology. Recurrent topics in Gary Calandra's work include Hematopoietic Stem Cell Transplantation (24 papers), Multiple Myeloma Research and Treatments (21 papers) and Acute Myeloid Leukemia Research (15 papers). Gary Calandra is often cited by papers focused on Hematopoietic Stem Cell Transplantation (24 papers), Multiple Myeloma Research and Treatments (21 papers) and Acute Myeloid Leukemia Research (15 papers). Gary Calandra collaborates with scholars based in United States, Germany and Canada. Gary Calandra's co-authors include Gary Bridger, Karin Badel, John F. DiPersio, Stefan Früehauf, Patrick J. Stiff, Ivana N. Micallef, Richard T. Maziarz, Auayporn Nademanee, Guido Tricot and Edward A. Stadtmauer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JAIDS Journal of Acquired Immune Deficiency Syndromes.

In The Last Decade

Gary Calandra

41 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

2009 579 citations John F. DiPersio, Edward A. Stadtmauer et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gary Calandra United States	15	1.1k	693	500	307	199	41	1.7k
Karin Badel United States	14	1.0k 0.9×	766 1.1×	623 1.2×	296 1.0×	203 1.0×	27	1.6k
Paulo Vidal Campregher Brazil	12	429 0.4×	569 0.8×	950 1.9×	323 1.1×	188 0.9×	57	1.7k
Ruth Seggewiss Germany	16	722 0.6×	374 0.5×	567 1.1×	322 1.0×	384 1.9×	26	1.4k
Mireia Camós Spain	22	576 0.5×	547 0.8×	329 0.7×	502 1.6×	500 2.5×	57	1.8k
Friedrich Schuening United States	21	617 0.5×	198 0.3×	277 0.6×	195 0.6×	174 0.9×	61	1.0k
Robert E. Sobol United States	20	257 0.2×	797 1.2×	535 1.1×	645 2.1×	197 1.0×	43	1.8k
Janet Ayello United States	21	341 0.3×	705 1.0×	529 1.1×	368 1.2×	167 0.8×	117	1.3k
D. Rill United States	8	545 0.5×	445 0.6×	215 0.4×	550 1.8×	140 0.7×	10	1.3k
Ely Benaim United States	21	445 0.4×	412 0.6×	320 0.6×	372 1.2×	218 1.1×	75	1.3k
Amanda F. Cashen United States	16	1.1k 0.9×	450 0.6×	340 0.7×	642 2.1×	227 1.1×	72	1.6k

Countries citing papers authored by Gary Calandra

Since Specialization

Citations

This map shows the geographic impact of Gary Calandra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Calandra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Calandra more than expected).

Fields of papers citing papers by Gary Calandra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Calandra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Calandra. The network helps show where Gary Calandra may publish in the future.

Co-authorship network of co-authors of Gary Calandra

This figure shows the co-authorship network connecting the top 25 collaborators of Gary Calandra. A scholar is included among the top collaborators of Gary Calandra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary Calandra. Gary Calandra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Horwitz, Mitchell E., G D Long, Peter Holman, et al.. (2012). Efficacy and safety of hematopoietic stem cell remobilization with plerixafor+G-CSF in adult patients with germ cell tumors. Bone Marrow Transplantation. 47(10). 1283–1286. 13 indexed citations

Calandra, Gary, Gary Bridger, & Simon P. Fricker. (2010). CXCR4 in Clinical Hematology. Current topics in microbiology and immunology. 341. 173–191. 37 indexed citations

Flomenberg, Neal, Raymond L. Comenzo, Karin Badel, & Gary Calandra. (2010). Plerixafor (Mozobil®) Alone to Mobilize Hematopoietic Stem Cells from Multiple Myeloma Patients for Autologous Transplantation. Biology of Blood and Marrow Transplantation. 16(5). 695–700. 23 indexed citations

Früehauf, Stefan, Gerhard Ehninger, Kai Hübel, et al.. (2009). Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. Bone Marrow Transplantation. 45(2). 269–275. 50 indexed citations

Stewart, Douglas A., Clayton A. Smith, Ron MacFarland, & Gary Calandra. (2009). Pharmacokinetics and Pharmacodynamics of Plerixafor in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma. Biology of Blood and Marrow Transplantation. 15(1). 39–46. 72 indexed citations

DiPersio, John F., Edward A. Stadtmauer, Auayporn Nademanee, et al.. (2009). Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 113(23). 5720–5726. 579 indexed citations breakdown →

Tricot, Guido, Michele Cottler‐Fox, & Gary Calandra. (2009). Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplantation. 45(1). 63–68. 62 indexed citations

Gazitt, Yair, César O. Freytes, Cagla Akay, Karin Badel, & Gary Calandra. (2007). Improved Mobilization of Peripheral Blood CD34 ⁺ Cells and Dendritic Cells by AMD3100 plus Granulocyte–Colony-Stimulating Factor in Non-Hodgkin's Lymphoma Patients. Stem Cells and Development. 16(4). 657–666. 43 indexed citations

Oelschlaegel, Uta, Martin Bornhäuser, Sabine Boxberger, et al.. (2007). Kinetics of CXCR-4 and adhesion molecule expression during autologous stem cell mobilisation with G-CSF plus AMD3100 in patients with multiple myeloma. Annals of Hematology. 86(8). 569–573. 22 indexed citations

10.

Calandra, Gary, John M. McCarty, Joseph P. McGuirk, et al.. (2007). AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplantation. 41(4). 331–338. 221 indexed citations

11.

MacFarland, R. T., et al.. (2007). Pharmacokinetics of Plerixafor (AMD3100) in Volunteers with Renal Impairment.. Blood. 110(11). 2878–2878. 5 indexed citations

12.

Früehauf, Stefan, Patrick Maier, Li Li, et al.. (2006). The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics. Experimental Hematology. 34(8). 1052–1059. 49 indexed citations

13.

Veldwijk, Marlon R., et al.. (2006). AMD3100 Inhibits Chemotaxis towards SDF-1 and CXCR4-Mediated Stroma-Contact in a Dose-Dependent Manner, Resulting in Increased Susceptibility to Imatinib.. Blood. 108(11). 4799–4799. 2 indexed citations

14.

Smith, Clayton A., et al.. (2006). AMD3100 with G-CSF for Autologous Peripheral Blood Progenitor Cell (PBPC) Mobilization in Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma (MM): Mobilization, Engraftment, and Pharmacokinetics (PK).. Blood. 108(11). 3383–3383. 5 indexed citations

15.

Schols, Dominique, Kurt Vermeire, Signe Fransen, et al.. (2005). Multi-drug resistant HIV-1 is sensitive to inhibition by chemokine receptor antagonists. 250. 3 indexed citations

16.

Maier, Patrick, Li Li, Stephanie Laufs, et al.. (2005). CD34+ Cells Mobilized with the New CXCR4 Antagonist AMD3100 + G-CSF Show Increased Anti-Apoptotic, Cell Cycle, DNA Repair and Cell Motility-Associated Gene Expression When Compared to G-CSF Mobilization Alone.. Blood. 106(11). 4264–4264. 1 indexed citations

17.

Schols, Dominique, Kurt Vermeire, Sigrid Hatse, et al.. (2004). In vitro anti-HIV activity profile of AMD887, a novel CCR5 antagonist, in combination with the CXCR4 inhibitor AMD070. 5 indexed citations

18.

Devine, Steven M., Jesper Bonde, David A. Hess, et al.. (2004). A Pilot Study Evaluating the Safety and Efficacy of AMD3100 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients with Advanced Hematological Malignancies.. Blood. 104(11). 3341–3341. 14 indexed citations

19.

Hendrix, Craig W., Ann C. Collier, Michael M. Lederman, et al.. (2004). Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, a Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes. 37(2). 1253–1262. 284 indexed citations

20.

Schols, Dominique, Sandra Claes, Sigrid Hatse, et al.. (2003). Anti-HIV activity profile of AMD070, an orally bioavailable CXCR4 antagonist. Antiviral Research. 57(3). 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact